doi:10.3969/j.issn.1004-583X.2022.06.017

Abstract

CLC Number:

R730.26

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.06.017

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I6/564

References 37

[1]	Singh T, Fatehi Hassanabad M, Fatehi Hassanabad A. Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2):188636. doi: 10.1016/j.bbcan.2021.188636 URL
[2]	Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer[J]. Lancet, 2021, 398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3 URL
[3]	Suzuki T. Regulation of the intestinal barrier by nutrients: The role of tight junctions[J]. Anim Sci J, 2020, 91(1):e13357.
[4]	Otani T, Furuse M. Tight junction structure and function revisited[J]. Trends Cell Biol, 2020, 30(10):805-817. doi: 10.1016/j.tcb.2020.08.004 URL
[5]	Piontek J, Krug SM, Protze J, et al. Molecular architecture and assembly of the tight junction backbone[J]. Biochim Biophys Acta Biomembr, 2020, 1862(7):183279. doi: 10.1016/j.bbamem.2020.183279 URL
[6]	Gowrikumar S, Singh AB, Dhawan P. Role of claudin proteins in regulating cancer stem cells and chemoresistance-potential implication in disease prognosis and therapy[J]. Int J Mol Sci, 2019, 21(1):53. doi: 10.3390/ijms21010053 URL
[7]	Popova OP, Kuznetsova AV, Bogomazova SY, et al. Claudins as biomarkers of differential diagnosis and prognosis of tumors[J]. J Cancer Res Clin Oncol, 2021, 147(10):2803-2817. doi: 10.1007/s00432-021-03725-0 pmid: 34241653
[8]	Bhat AA, Syed N, Therachiyil L, et al. Claudin-1, a double-edged sword in cancer[J]. Int J Mol Sci, 2020, 21(2):569. doi: 10.3390/ijms21020569 URL
[9]	Kolchakova D, Moten D, Batsalova T, et al. Tight junction protein claudin-12 is involved in cell migration during metastasis[J]. Biomolecules, 2021, 11(5):636. doi: 10.3390/biom11050636 URL
[10]	Du H, Yang X, Fan J, et al. Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review)[J]. Mol Med Rep, 2021, 24(3):677. doi: 10.3892/mmr.2021.12316 URL
[11]	Osanai M, Takasawa A, Murata M, et al. Claudins in cancer: Bench to bedside[J]. Pflugers Arch, 2017, 469(1):55-67. doi: 10.1007/s00424-016-1877-7 URL
[12]	Lv J, Sun B, Mai Z, et al. CLDN-1 promoted the epithelial to migration and mesenchymal transition (EMT) in human bronchial epithelial cells via Notch pathway[J]. Mol Cell Biochem, 2017, 432(1-2):91-98. doi: 10.1007/s11010-017-3000-6 URL
[13]	Chao YC, Pan SH, Yang SC, et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma[J]. Am J Respir Crit Care Med, 2009, 179(2):123-133. doi: 10.1164/rccm.200803-456OC URL
[14]	Merikallio H, Kaarteenaho R, Pääkkö P, et al. Impact of smoking on the expression of claudins in lung carcinoma[J]. Eur J Cancer, 2011, 47(4):620-630. doi: 10.1016/j.ejca.2010.10.017 pmid: 21106366
[15]	Zhang Z, Wang A, Sun B, et al. Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma[J]. J Cardiothorac Surg, 2013, 8:95. doi: 10.1186/1749-8090-8-95 URL
[16]	Wu JE, Wu YY, Tung CH, et al. DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression[J]. Theranostics, 2020, 10(19):8903-8923. doi: 10.7150/thno.45785 URL
[17]	Pyo JS, Kim NY, Cho WJ. Prognostic role of claudin-1 immunohistochemistry in malignant solid tumors: A meta-analysis[J]. J Pathol Transl Med, 2019, 53(3):173-179. doi: 10.4132/jptm.2019.02.03 URL
[18]	Sun BS, Yao YQ, Pei BX, et al. Claudin-1 correlates with poor prognosis in lung adenocarcinoma[J]. Thorac Cancer, 2016, 7(5):556-563. doi: 10.1111/1759-7714.12368 URL
[19]	Ma L, Yin W, Ma H, et al. Targeting claudin-3 suppresses stem cell-like phenotype in nonsquamous non-small-cell lung carcinoma[J]. Lung Cancer Manag, 2019, 8(1):LMT04. doi: 10.2217/lmt-2018-0010 URL
[20]	Che J, Yang Y, Xiao J, et al. Decreased expression of claudin-3 is associated with a poor prognosis and EMT in completely resected squamous cell lung carcinoma[J]. Tumour Biol, 2015, 36(8):6559-6568. doi: 10.1007/s13277-015-3350-1 URL
[21]	Che J, Yue D, Zhang B, et al. Claudin-3 inhibits lung squamous cell carcinoma cell epithelial-mesenchymal transition and invasion via suppression of the Wnt/β-catenin signaling pathway[J]. Int J Med Sci, 2018, 15(4):339-351. doi: 10.7150/ijms.22927 URL
[22]	Zhang L, Wang Y, Zhang B, et al. Claudin-3 expression increases the malignant potential of lung adenocarcinoma cells: Role of epidermal growth factor receptor activation[J]. Oncotarget, 2017, 8(14):23033-23047. doi: 10.18632/oncotarget.14974 URL
[23]	Qu H, Qi D, Wang X, et al. CLDN6 suppresses c-MYC-mediated aerobic glycolysis to inhibit proliferation by TAZ in breast cancer[J]. Int J Mol Sci, 2021, 23(1):129. doi: 10.3390/ijms23010129 URL
[24]	Qu H, Jin Q, Quan C. CLDN6: From traditional barrier function to emerging roles in cancers[J]. Int J Mol Sci, 2021, 22(24):13416. doi: 10.3390/ijms222413416 URL
[25]	Kojima M, Sugimoto K, Tanaka M, et al. Prognostic significance of aberrant claudin-6 expression in endometrial cancer[J]. Cancers (Basel), 2020, 12(10):2748. doi: 10.3390/cancers12102748 URL
[26]	Reinhard K, Rengstl B, Oehm P, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors[J]. Science, 2020, 367(6476):446-453. doi: 10.1126/science.aay5967 URL
[27]	Micke P, Mattsson JS, Edlund K, et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer[J]. Int J Cancer, 2014, 135(9):2206-2214. doi: 10.1002/ijc.28857 URL
[28]	Zhang C, Guo C, Li Y, et al. Identification of claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis[J]. Front Cell Dev Biol, 2021, 9:726656. doi: 10.3389/fcell.2021.726656 URL
[29]	Wang Q, Zhang Y, Zhang T, et al. Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer[J]. Onco Targets Ther, 2015, 8:1971-1977.
[30]	Wang K, Xu C, Li W, et al. Emerging clinical significance of claudin-7 in colorectal cancer: A review[J]. Cancer Manag Res, 2018, 10:3741-3752. doi: 10.2147/CMAR.S175383 pmid: 30288105
[31]	Akizuki R, Shimobaba S, Matsunaga T, et al. Claudin-5, -7, and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma[J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(2):293-302. doi: 10.1016/j.bbamcr.2016.11.018 URL
[32]	Lu Z, Kim DH, Fan J, et al. A non-tight junction function of claudin-7-Interaction with integrin signaling in suppressing lung cancer cell proliferation and detachment[J]. Mol Cancer, 2015, 14:120. doi: 10.1186/s12943-015-0387-0 URL
[33]	Kim DH, Lu Q, Chen YH. Claudin-7 modulates cell-matrix adhesion that controls cell migration, invasion and attachment of human HCC827 lung cancer cells[J]. Oncol Lett, 2019, 17(3):2890-2896.
[34]	Zheng Z, Lin K, Hu Y, et al. Sulforaphane metabolites inhibit migration and invasion via microtubule-mediated Claudins dysfunction or inhibition of autolysosome formation in human non-small cell lung cancer cells[J]. Cell Death Dis, 2019, 10(4):259. doi: 10.1038/s41419-019-1489-1 URL
[35]	Lu Z, Liu Y, Xu J, et al. Immunohistochemical quantification of expression of a tight junction protein, claudin-7, in human lung cancer samples using digital image analysis method[J]. Comput Methods Programs Biomed, 2018, 155:179-187. doi: 10.1016/j.cmpb.2017.12.014 URL
[36]	Kyuno D, Takasawa A, Kikuchi S, et al. Role of tight junctions in the epithelial-to-mesenchymal transition of cancer cells[J]. Biochim Biophys Acta Biomembr, 2021, 1863(3):183503. doi: 10.1016/j.bbamem.2020.183503 URL
[37]	Li J. Targeting claudins in cancer: diagnosis, prognosis and therapy[J]. Am J Cancer Res, 2021, 11(7):3406-3424.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 37

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yi Peng, Li Cuiling, Huang Xinjiang, Zeng Chunhua. Clinical analysis of 5 cases with precocious puberty caused by hypothalamic hamartomas treated with gonadotropin releasing hormone analogues [J]. Clinical Focus, 2024, 39(1): 53-56.
[2]	Tao Jianan, Li Wenqian, Ma Xiuwen, An Qi, Wang Xuehong. Meta-analysis of expression and clinical significance of HER-2 in hepatocellular carcinoma [J]. Clinical Focus, 2023, 38(12): 1067-1072.
[3]	Zhang Na, Sun Yue, Dong Han, Zhao Peng, Yang Xin, Qi Yuan, Wang Lingling. Correlation between the expression level of SPARC and prognosis in patients with non-small cell lung cancer: A meta-analysis [J]. Clinical Focus, 2023, 38(11): 972-978.
[4]	Liu Fei, Lin Zhichun, Yue Jianlan, Yin Liang, Huang Shiming. Meta-analysis of different positron emission tomography/computed tomography imaging agents in the diagnosis of gliomas [J]. Clinical Focus, 2023, 38(4): 302-307.
[5]	He Chendong, Ge Fenglin, Yang Wei. TFEB translocation renal cell carcinoma: A case and literature review [J]. Clinical Focus, 2022, 37(12): 1122-1126.
[6]	Jia Chengbang, Shen Lijuan, Sun Zhigang. The relationship between CEA, CA125 and NSE and the pathological characteristics of patients with NSCLC and the value of combined detection [J]. Clinical Focus, 2022, 37(11): 992-995.
[7]	He Chao, Huang Shaobin. Predicting the risk by FIB-4 on hepatocellular carcinoma in patients with chronic liver disease: A meta-analysis [J]. Clinical Focus, 2022, 37(9): 779-784.
[8]	Peng Yu, Jiang Zhihong, Wang Zhihai. Clinical and genetic analysis of a neonate with congenital central nervous system multiple malformation: An identification on mutations in VANGL1 genes [J]. Clinical Focus, 2022, 37(7): 640-643.
[9]	. [J]. Clinical Focus, 2022, 37(7): 663-667.
[10]	Li Qing, Zhong Wen, Liu Siqiang, Chen Yusheng, Li Hongru. Meta-analysis of PD-1/PD-L1 inhibitors in the treatment of patients with non-small cell lung cancer having brain metastases [J]. Clinical Focus, 2022, 37(5): 400-405.
[11]	He Yiwen, Qiao Tiankui. Clinical value of CEA, CA125, and CYFRA21-1 levels in efficacy evaluation of EGFR-TKIs in the treatment of EGFR mutation-positive non-small cell lung adenocarcinoma [J]. Clinical Focus, 2021, 36(3): 220-224.
[12]	Ye Dan, Zhang Jiabo, Yao Lingli, Guo Yu. Relations between the expression of cyclinD1, p27 and the ultrasonographic features of central lymph node metastasis in the PTMC [J]. Clinical Focus, 2021, 36(3): 262-265.
[13]	Bao Xinran, Ha Minwen. Prognostic value of NLR, PLR and CEA in advanced non-small cell lung cancer [J]. Clinical Focus, 2021, 36(2): 139-143.
[14]	Zhang Zhaoming, Yu Xiangfeng, Song Jihui. Application value of diffusionweighted magnetic resonance imaging combined with spectral imaging in evaluating glioma grade [J]. Clinical Focus, 2020, 35(12): 1106-1110.
[15]	. [J]. Clinical Focus, 2020, 35(12): 1137-1141.